Edition:
United States

Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.51AUD
26 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.51
Open
$0.53
Day's High
$0.55
Day's Low
$0.50
Volume
234,899
Avg. Vol
75,138
52-wk High
$0.55
52-wk Low
$0.22

Summary

Name Age Since Current Position

Roger Aston

2012 Non-Executive Chairman of the Board

Thomas Liquard

43 2015 Chief Executive Officer

Peter Anastasiou

2015 Executive Vice Chairman of the Board

Jerry Kanellos

2015 Chief Operating and Scientific Officer

Phillip Hains

2013 Joint Company Secretary

Peter Vaughan

2013 Joint Company Secretary

Ravi Savarirayan

2017 Director

Stephen Anastasiou

2013 Non-Executive Director

Daniel Pollock

2012 Independent Non-Executive Director

Biographies

Name Description

Roger Aston

Dr. Roger Aston, Ph.D., is Non-Executive Chairman of the Board of Immuron Limited since October 8, 2012. He was appointed Non-Executive Director on May 5, 2012. Within the Company he is Member of Audit and Risks Committee. Dr. Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited. Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK – now Bio Focus plc). Dr. Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr. Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr. Aston has been closely involved in the development of a number of pharmaceutical and biotechnology companies. Dr. Aston has experience including negotiating global license agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. Other current directorships include IDT Limited.

Thomas Liquard

Mr. Thomas Liquard has been appointed as Chief Executive Officer of the Company., effective 31 August 2015. Mr Liquard has held various commercialisation, product development and leadership roles with large pharma and biotech companies and holds an MBA from Columbia Business School and a Bachelor of Science degree from the University of Southern California. From 2013 to 2014, Mr. Liquard was Chief Operating Officer (COO) of major Australian biotech company Alchemia Limited (ASX:ACL) before then becoming CEO of the Company. Throughout his time will Alchemia, Mr Liquard managed a $22M operating budget, brought two major investors onto the register, and led all major business development and corporate development activities for the company. Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer in New York, where he held various commercial roles of increasing scope and responsibility. In his most recent role with Pfizer as the Senior Director, Portfolio Development Leader Emerging Markets for the Established Products, Mr. Liquard was pivotal to driving business development (M&A, licensing, partnerships) and internal product development initiatives which involved managing more than 70 opportunities at various stages of execution. During his tenure at Pfizer, Mr. Liquard also spent three years as a key member of Pfizer’s Established Products US Brands P&L Leadership Team where he engineered the group’s 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals, Inc. (NextWave), where Mr Liquard led the pre-and post-acquisition integration efforts of NextWave into the existing Pfizer business. From 2004 to 2007, Mr. Liquard served as a Senior Consultant with the Frankel Group, where he specialised in the life sciences.

Peter Anastasiou

Mr. Peter Anastasiou is Executive Vice Chairman of the Board of Immuron Limited. Mr. Anastasiou was the founding Chairman of the ACSI Group of Companies, which has owned and managed successful consumer companies such as SABCO, Britex Carpet care, Rug Doctor and Crystal Clear. Mr Anastasiou also has a number of philanthropic interests including being a patron of the Identity Theatre for men, a prior board member and supporter of the Indigenous Eye Health Unit at Melbourne University, a supporter of the John Fawcett Foundation in Bali, and a founding investor and Director of Melbourne Victory Football Club.

Jerry Kanellos

Dr. Jerry Kanellos has been appointed as Chief Operating and Scientific Officer of the Company., with effect from 28 July 2015. Dr Jerry Kanellos has over twenty years experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management, research and development and senior management, and holds a PhD in Medicine from the University of Melbourne. Dr. Kanellos spent five years with TransBio Limited where as Chief Operating Officer, he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property portfolio, research & development and technology transfer. Prior to this, Dr. Kanellos work for five years as a consultant to the biotech industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.

Phillip Hains

Mr. Phillip Hains is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Hains is a Chartered Accountant and specialist in the public company environment. He services the needs of a number of public company boards and related committees as both their Company Secretary and Chief Financial Officer. He has had over 20 years’ experience in providing accounting, administration, compliance and general management services to both ASX and NASDAQ listed companies.

Peter Vaughan

Mr. Peter Vaughan is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Vaughan is also a Chartered Accountant who has worked in the listed company environment for 10 years across a number of industries serving various finance roles, including the roles of Company Secretary and Chief Financial Officer.

Ravi Savarirayan

Prof. Ravi Savarirayan serves as Director of the Company. Ravi is a consultant clinical geneticist at the Victorian Clinical Genetics Services, as well as Professor and Research Group Leader (Skeletal Biology and Disease) at the Murdoch Childrens Research Institute. Ravi received his MBBS from the University of Adelaide in 1990 and became a fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in clinical genetics from the Human Genetics Society of Australasia in 1998 and received his Doctor of Medicine from the University of Melbourne in 2004, for his thesis “Clinical and molecular studies in the osteochondrodysplasias.” He is a founding member of the Skeletal Dysplasia Management Consortium and has been the Chair of the Specialist Advisory Committee in Clinical Genetics, Royal Australasian College of Physicians since 2009. He was president of the International Skeletal Dysplasia Society from 2009 to 2011 and has been an invited member of several International Working Committees on Constitutional Diseases of Bone. Ravi's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with peers from over 30 countries, and is on the editorial board of Human Mutation, European Journal of Human Genetics, American Journal of Medical Genetics and Journal of Medical Genetics.

Stephen Anastasiou

Mr. Stephen Anastasiou is Non-Executive Director of Immuron Ltd effective May 28, 2013. He holds a Bachelor of Science (Hons), Graduate Diploma in Marketing and a Masters of Business Administration. He has over 20 years’ experience in general management, marketing and strategic planning within the healthcare industry. He is management consultant with KPMG Peat Marwick and Director and shareholder of a number of unlisted private companies. Mr. Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr Anastasiou’s companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.

Daniel Pollock

Mr. Daniel Pollock is Director of Immuron Ltd since October 11, 2012. Daniel Pollock is a lawyer admitted in both Scotland and Australia and holding Practicing Certificates in both Jurisdictions. He is sole practitioner in his own legal firm based in Melbourne, Australia which operates internationally and specializes in commercial law. Daniel is Chairman and Company Secretary of Amaero Pty Ltd, a company established to commercialise laser based additive manufacturing emerging from Monash University. He is also Executive Director and co-owner of Great Accommodation P/L a property management business operating in Victoria. Daniel has had historical involvement as a seed investor and Board member of a number of small unlisted companies. The most recent of these was an E-Pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company.